Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 9;25(26):3027-3041.
doi: 10.2174/0115680266336478241118065659. Online ahead of print.

Traditional Chinese Medicine for Liver Cancer Treatment: Network Pharmacology Research

Shihao Zheng  1 , Yixiao Gu  2 , Wenying Qi  1 , Wei Wang  1 , Xiaoke Li  1   3 , Xiaobin Zao  1   4 , Size Li  1 , Shaoyu Liu  5 , Tianyu Xue  6 , Yongan Ye  1   3 , Aimin Liu  7
Affiliations

Traditional Chinese Medicine for Liver Cancer Treatment: Network Pharmacology Research

Shihao Zheng et al. Curr Top Med Chem. .

Abstract

Background: As one of the common malignant tumors nowadays, liver cancer has more risk factors for its development and is characterized by a high recurrence rate, high mortality rate, and poor prognosis, which poses a great threat to people's health. The specific efficacy of traditional Chinese medicine is based on clinical practice, which is a high degree of generalization of the characteristics and scope of the clinical effects of prescription medicines and a special form of expression of the medical effects of the human body within the scope of traditional Chinese medicine. Because of its multi-ingredient, multi-target, and multi-pathway characteristics, it has a great advantage in the treatment of liver cancer. Still, at present, its specific molecular mechanism of action has not yet been clarified.

Aim: This study reviews the current status and characteristics of network pharmacology research in the treatment of liver cancer, aiming to provide new ideas and methods for traditional Chinese medicine treatment of the disease.

Methods: This study was searched on the Web of Science and PubMed using keywords, such as "traditional Chinese medicine", "liver cancer," and "network pharmacology." The citation dates of the literature cited in this review are from 2000 to 2024.

Results: The discovery of the key molecular mechanisms of traditional Chinese medicine in the treatment of liver cancer through the network pharmacology approach and the in-depth study of the related signaling pathways are conducive to a more in-depth exploration of traditional Chinese medicine.

Conclusion: Network pharmacology research plays a key role in the treatment and prevention of liver cancer and deserves deeper exploration in the future.

Keywords: Liver cancer; Network pharmacology; Research progress; Targets.; Traditional Chinese medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

Figures

Fig. (1)
Fig. (1)
Progression of liver cancer.
Fig. (2)
Fig. (2)
Liver cancer and network pharmacology.
See this image and copyright information in PMC

References

    1. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology. 2010;51(5):1820–1832. doi: 10.1002/hep.23594. - DOI - PubMed
    1. Center M.M., Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol. Biomarkers Prev. 2011;20(11):2362–2368. doi: 10.1158/1055-9965.EPI-11-0643. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 2019;69(1):7–34. doi: 10.3322/caac.21551. - DOI - PubMed
    1. Anwanwan D., Singh S.K., Singh S., Saikam V., Singh R. Challenges in liver cancer and possible treatment approaches. Biochim. Biophys. Acta Rev. Cancer. 2020;1873(1):188314. doi: 10.1016/j.bbcan.2019.188314. - DOI - PMC - PubMed
    1. Akinyemiju T., Abera S., Ahmed M., Alam N., Alemayohu M.A., Allen C., Al-Raddadi R., Alvis-Guzman N., Amoako Y., Artaman A., Ayele T.A., Barac A., Bensenor I., Berhane A., Bhutta Z., Castillo-Rivas J., Chitheer A., Choi J.Y., Cowie B., Dandona L., Dandona R., Dey S., Dicker D., Phuc H., Ekwueme D.U., Zaki M.E.S., Fischer F., Fürst T., Hancock J., Hay S.I., Hotez P., Jee S.H., Kasaeian A., Khader Y., Khang Y.H., Kumar G.A., Kutz M., Larson H., Lopez A., Lunevicius R., Malekzadeh R., McAlinden C., Meier T., Mendoza W., Mokdad A., Moradi-Lakeh M., Nagel G., Nguyen Q., Nguyen G., Ogbo F., Patton G., Pereira D.M., Pourmalek F., Qorbani M., Radfar A., Roshandel G., Salomon J.A., Sanabria J., Sartorius B., Satpathy M., Sawhney M., Sepanlou S., Shackelford K., Shore H., Sun J., Mengistu D.T., Topór-Madry R., Tran B., Ukwaja K.N., Vlassov V., Vollset S.E., Vos T., Wakayo T., Weiderpass E., Werdecker A., Yonemoto N., Younis M., Yu C., Zaidi Z., Zhu L., Murray C.J.L., Naghavi M., Fitzmaurice C. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol. 2017;3(12):1683–1691. doi: 10.1001/jamaoncol.2017.3055. - DOI - PMC - PubMed